natgillin/translations-raw huggingface dataset:
c P-value for the superiority test comparing the percentages of virologic success was from the CMH test stratified by the prior treatment regimen (EFV/FTC/tenofovir disoproxil, FTC/tenofovir disoproxil plus boosted atazanavir, or 
c P-vrijednost za test superiornosti kojim su uspoređeni postotci virološkog uspjeha iz CMH testa stratificirano prema prvotnom režimu liječenja (EFV/FTC/tenofovirdizoproksil, FTC/tenofovirdizoproksil plus pojačani atazanavir ili E/C/F/TDF).
The safety and efficacy of Genvoya in patients with significant underlying liver disorders have not been established. 
Sigurnost i djelotvornost primjene lijeka Genvoya u bolesnika s postojećim značajnim bolestima jetre nisu ustanovljene.
If Genvoya is stopped for any reason, speak to your doctor before you restart taking Genvoya tablets. 
Ako zbog bilo kojeg razloga prestanete uzimati lijek Genvoya, porazgovarajte s liječnikom prije nego što ponovno počnete uzimati tablete lijeka Genvoya.
There is insufficient information on the effects of elvitegravir, cobicistat, emtricitabine and tenofovir in newborns/infants. 
Nema dovoljno podataka o učincima elvitegravira, kobicistata, emtricitabina i tenofovira na novorođenčad/dojenčad.
Each bottle contains silica gel desiccant and polyester coil. 
Jedna boca sadrži sredstvo za sušenje (silika gel) i poliestersku vaticu.
In animal studies it has been shown that elvitegravir, cobicistat, and tenofovir are excreted in milk. 
Ispitivanja na životinjama pokazala su da se elvitegravir, kobicistat i tenofovir izlučuju u mlijeko životinja.
No in vitro resistance can be demonstrated with cobicistat due to its lack of antiviral activity. 
Nije zapažena in vitro rezistencija za kobicistat zbog nedostatka njegovog antivirusnog djelovanja.
The median terminal plasma half-life of cobicistat following administration of E/C/F/TDF is approximately 3.5 hours and the associated cobicistat exposures provide elvitegravir Ctrough approximately 10-fold above the protein-binding adjusted IC95 for wild-type HIV-1 virus. 
Medijan poluvremena kobicistata u plazmi nakon primjene E/C/F/TDF iznosi oko 3,5 sati, a povezane izloženosti kobicistatu omogućuju Ctrough elvitegravira oko 10 puta višu od prilagođene vrijednosti IC95 vezivanja proteina za divlji tip virusa HIV-1.
Viruses expressing elvitegravir or raltegravir resistance mutations maintain susceptibility to dolutegravir. 
Virusi koji izražavaju mutacije povezane s rezistencijom na elvitegravir ili raltegravir zadržavaju osjetljivost na dolutegravir.
HIV-1 isolates with reduced susceptibility to tenofovir alafenamide express a K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been transiently observed. 
Izolati virusa HIV-1 sa smanjenom osjetljivošću na tenofoviralafenamid izražavaju mutaciju K65R u HIV-1 RT; dodatno je kratkotrajno uočena i mutacija K70E u HIV-1 RT.
E/C/F/TDF = elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate a Week 48 window was between Day 294 and 377 (inclusive); Week 144 window was between Day 966 and 1,049 (inclusive). 
E/C/F/TDF = elvitegravir/kobicistat/emtricitabin/tenofovirdizoproksilfumarat a Okvir 48. tjedna bio je između 294. i 377. dana (uključivo); okvir 144. tjedna bio je između 966. i 1049. dana (uključivo).
The K65R and K70E mutations result in reduced susceptibility to abacavir, didanosine, lamivudine, emtricitabine, and tenofovir, but retain sensitivity to zidovudine. 
Mutacije K65R i K70E imale su za posljedicu smanjenu osjetljivost na abakavir, didanozin, lamivudin, emtricitabin i tenofovir, ali zadržanu osjetljivost na zidovudin.
Mean % change of elvitegravir pharmacokinetic parametersa 
Srednja vrijednost % promjene farmakokinetičkih parametara elvitegraviraa
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 µg/mL. 
In vitro vezanje emtricitabina za humane proteine plazme bilo je < 4% i nije ovisilo o koncentraciji u rasponu od 0,02-200 µg/ml.
The adverse reactions in Table 2 are listed by system organ class and frequency. 
Nuspojave u Tablici 2 navedene su prema klasifikaciji organskih sustava i učestalosti.
Of the 62 patients who were HBV suppressed at baseline, 59 remained suppressed and 3 had missing data. 
Od 62 bolesnika koji su imali supresiju HBV-a na početku, 59 ih je zadržalo supresiju, a za 3 bolesnika podaci nisu poznati.
Table 2: Tabulated list of adverse reactions 
Tablica 2: Tablični prikaz nuspojava
At the start of treatment with Genvoya, the 72 patients had been HIV suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months with or without suppression of HBV DNA and had compensated liver function. 
Na početku liječenja lijekom Genvoya, 72 bolesnika imali su supresiju HIV-a (HIV-1 RNK < 50 kopija/ml) najmanje 6 mjeseci sa ili bez supresije HBV DNA i imali su kompenziranu funkciju jetre.
The safety of Genvoya has not been established in patients with severe renal impairment (estimated CrCl ≥ 15 mL/min and < 30 mL/min). 
Sigurnost lijeka Genvoya nije ustanovljena u bolesnika s teškim oštećenjem funkcije bubrega (procijenjeni CrCl ≥ 15 ml/min i < 30 ml/min).
Other medicines and Genvoya Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
Plasma concentrations of these medicinal products may be increased when co-administered with Genvoya, resulting in reduced serum cortisol concentrations. 
Mogu biti povećane koncentracije tih lijekova u plazmi kada se primjenjuju istodobno s lijekom Genvoya, što dovodi do smanjenih koncentracija kortizola u serumu.
In studies GS-US-292-0104 and GS-US-292-0111, patients were randomised in a 1:1 ratio to receive either Genvoya (n = 866) once daily or elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg (E/C/F/TDF) (n = 867) once daily. 
U ispitivanjima GS-US-292-0104 i GS-US-292-0111 bolesnici su bili randomizirani u omjeru 1:1 kako bi primali lijek Genvoya (n = 866) jednom dnevno ili elvitegravir 150 mg/kobicistat 150 mg/emtricitabin 200 mg/tenofovirdizoproksil (u obliku fumarata) 245 mg (E/C/F/TDF) (n = 867) jednom dnevno.
In a study of Genvoya in HIV-1 infected adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis, efficacy was maintained through 48 weeks but emtricitabine exposure was significantly higher than in patients with normal renal function. 
U ispitivanju lijeka Genvoya u odraslih zaraženih virusom HIV-1 sa završnim stadijem bolesti bubrega (procijenjeni CrCl < 15 ml/min) na kroničnoj hemodijalizi, djelotvornost je bila održana tijekom 48 tjedana, ali izloženost emtricitabinu bila je značajno viša nego u bolesnika s normalnom funkcijom bubrega.
Cobicistat was not mutagenic or clastogenic in conventional genotoxicity assays. 
Kobicistat nije pokazao mutagenost ni klastogenost u konvencionalnim pretragama genotoksičnosti.
Concomitant use of Genvoya and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression. 
Genvoya i kortikosteroida koji se metaboliziraju putem CYP3A (npr. flutikazonpropionata ili drugih inhalacijskih ili nazalnih kortikosteroida) može se povećati rizik od razvoja sistemskih učinaka kortikosteroida, uključujući Cushingov sindrom i adrenalnu supresiju.
The hormonal contraceptive should contain at least 30 µg ethinyloestradiol and contain drospirenone or norgestimate as the progestogen or patients should use an alternative reliable method of contraception (see sections 4.4 and 
Hormonska kontracepcija mora sadržavati najmanje 30 µg etinilestradiola i mora sadržavati drospirenon ili norgestimat kao progestagen ili bolesnice moraju primjenjivati drugu pouzdanu metodu kontracepcije (vidjeti dijelove 4.4 i 4.6).
Co-administration is contraindicated with medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious or life-threatening adverse reactions. 
Kontraindicirana je istodobna primjena s lijekovima čiji klirens uvelike ovisi o CYP3A i kod kojih su povišene koncentracije u plazmi povezane s ozbiljnim ili životno opasnim nuspojavama.
Tenofovir alafenamide is minimally metabolised by CYP3A4. 
Tenofoviralafenamid se minimalno metabolizira pomoću CYP3A4.
• elvitegravir, an antiretroviral medicine known as an integrase inhibitor 
• elvitegravir, antiretrovirusni lijek poznat kao inhibitor integraze
Improvements in BMD were noted at 96 weeks after switching to Genvoya from a tenofovir disoproxil-containing regimen compared to maintaining the tenofovir disoproxil-containing regimen. 
Poboljšanja BMD-a bila su opažena 96 tjedana nakon prebacivanja s režima koji sadrži tenofovirdizoproksil na lijek Genvoya u usporedbi s ostankom na režimu koji sadrži tenofovirdizoproksil.
ANTI-INFECTIVES Antifungals 
ANTIINFEKTIVNI LIJEKOVI
7 This study was conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in 
To je ispitivanje provedeno s dodatnom dozom voksilaprevira od 100 mg kako bi se postigle izloženosti voksilapreviru očekivane u bolesnika zaraženih HCV-om.
1 This adverse reaction was not observed in the Phase 3 clinical studies for Genvoya but identified from clinical studies or post-marketing experience for emtricitabine when used with other antiretrovirals. 
1 Ova nuspojava nije uočena u fazi 3 kliničkih ispitivanja lijeka Genvoya ali je prepoznata u kliničkim ispitivanjima ili nakon stavljanja lijeka u promet za emtricitabin kad se koristio s drugim antiretrovirusnim lijekovima.
Co-administration of Genvoya and rifabutin is not recommended. 
Ne preporučuje se istodobna primjena lijeka Genvoya i rifabutina.
If you vomit less than 1 hour after taking Genvoya, take another tablet with food. 
Ako povratite unutar 1 sata od uzimanja lijeka Genvoya, uzmite drugu tabletu s hranom.
• medicines used to treat gout: 
• lijekove koji se primjenjuju za liječenje gihta:
Switching from a tenofovir disoproxil-based regimen to Genvoya was superior in maintaining HIV-1 RNA < 50 copies/mL compared to staying on the baseline regimen (Table 4). 
Prebacivanje s režima temeljenog na tenofovirdizoproksilu na lijek Genvoya bilo je superiorno u održavanju HIV-1 RNK < 50 kopija/ml u usporedbi s ostankom na početnom režimu (Tablica 4).
Baseline regimen (n = 477) 
(n = 477)
 If you notice any of these symptoms, tell your doctor immediately. 
Ako primijetite neki od ovih simptoma, odmah o tome obavijestite svog liječnika.
A study of the pharmacokinetics of cobicistat-boosted elvitegravir was performed in non-HIV-1 infected patients with moderate hepatic impairment (Child-Pugh Class B). 
Ispitivanje farmakokinetike kobicistatom pojačanog elvitegravira provedeno je na bolesnicima koji nisu zaraženi virusom HIV-1, a koji imaju umjereno oštećenje funkcije jetre (Child-Pugh, stadij B).
Antiviral synergy was maintained for elvitegravir, emtricitabine, and tenofovir alafenamide when tested in the presence of cobicistat. 
Antivirusna sinergija održana je za elvitegravir, emtricitabin i tenofoviralafenamid prilikom ispitivanja u prisutnosti kobicistata.
Cobicistat is a selective, mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A subfamily. 
Kobicistat je selektivni inhibitor enzima citokrom P450 (CYP) temeljeno na mehanizmu, iz podporodice CYP3A enzima.
Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir alafenamide compared to tenofovir disoproxil, carcinogenicity studies and a rat peri-postnatal study were conducted only with tenofovir disoproxil. 
Budući da je izloženost tenofoviru u štakora i miševa nakon primjene tenofoviralafenamida manja nego pri primjeni tenofovirdizoproksila, ispitivanja kancerogenosti te perinatalno i postnatalno ispitivanje u štakora provedena su samo s tenofovirdizoproksilom.
Tenofovir has activity against HIV-1, HIV-2, and HBV. 
Tenofovir je aktivan protiv virusa HIV-1, HIV-2 i HBV.
Co-administration of Genvoya with medicinal products that induce CYP3A may result in decreased plasma concentrations of elvitegravir and reduced therapeutic effect of Genvoya (see “Concomitant use contraindicated” and section 4.3). 
Istodobna primjena lijeka Genvoya s lijekovima koji induciraju CYP3A može imati za posljedicu smanjenu koncentraciju elvitegravira u plazmi i smanjen terapijski učinak lijeka Genvoya (vidjeti „Kontraindicirana istodobna primjena“ i dio 4.3).
Cobicistat is metabolised via CYP3A (major)- and CYP2D6 (minor)-mediated oxidation and does not undergo glucuronidation. 
Kobicistat se metabolizira putem CYP3A (uglavnom) i oksidacije posredovane CYP2D6 (manje) te ne prolazi kroz glukuronidaciju.
No dose adjustment of Genvoya is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. 
Nije potrebna prilagodba doze lijeka Genvoya u bolesnika s blagim (Child-Pugh stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem funkcije jetre.
3.7% (95% CI: 0.4% to 7.0%, p < 0.017c) 
3,7% (95% CI: 0,4% do 7,0%, p < 0,017c)
Fifteen percent of patients identified as Hispanic/Latino. 
Petnaest posto bolesnika izjasnilo se kao Hispanoamerikanci/Latinoamerikanci.
Cobicistat has no detectable antiviral activity against HIV-1 and does not antagonise the antiviral effects of elvitegravir, emtricitabine, or tenofovir. 
Za kobicistat nije otkrivena antivirusna aktivnost na HIV-1, te on ne antagonizira antivirusne učinke elvitegravira, emtricitabina ili tenofovira.
Tenofovir alafenamide is transported by P-gp and BCRP. 
Tenofoviralafenamid se transportira P-gp-om i BCRP-om.
If the patient vomits within 1 hour of taking Genvoya another tablet should be taken. 
Ako bolesnik povraća unutar 1 sata od uzimanja lijeka Genvoya, mora uzeti drugu tabletu.
Plasma concentrations of drospirenone are expected to be increased following co-administration with Genvoya and clinical monitoring is recommended due to the potential for hyperkalaemia (see section 4.5). 
Budući da se očekuje da će se nakon istodobne primjene s lijekom Genvoya koncentracije drospirenona u plazmi povećati, preporučuje se kliničko praćenje zbog moguće pojave hiperkalijemije (vidjeti dio 4.5).
Emtricitabine has activity against HIV-1, HIV-2, and HBV. 
Emtricitabin je aktivan protiv virusa HIV-1, HIV-2 i HBV.
c Includes patients who had ≥ 50 copies/mL in the Week 48 or 144 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL. 
c Obuhvatilo bolesnike koji su imali ≥ 50 kopija/ml u okviru 48. ili 144. tjedna; bolesnike koji su rano prestali primati ispitivani lijek zbog nedostatka ili gubitka djelotvornosti; bolesnike koji su prekinuli liječenje iz razloga koji nisu posljedica nuspojava, smrti ili nedostatka ili gubitka djelotvornosti i koji su u vrijeme prekida liječenja imali virusnu vrijednost ≥ 50 kopija/ml.
In vitro binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 µg/mL. 
In vitro vezanje tenofovira za humane proteine plazme je < 0,7% i ne ovisi o koncentraciji u rasponu od 0,01-25 µg/ml.
2 This adverse reaction was not observed in the Phase 3 clinical studies for Genvoya but identified from clinical studies for elvitegravir when used with other antiretrovirals. 
Ova nuspojava nije uočena u fazi 3 kliničkih ispitivanja lijeka Genvoya ali je prepoznata u kliničkim ispitivanjima elvitegravira kad se koristio s drugim antiretrovirusnim lijekovima
Ninety-two percent (66/72 patients) had HBV DNA < 29 IU/mL using missing = failure analysis at Week 48. 
Devedeset dva posto (66/72 bolesnika) imalo je HBV DNA < 29 IU/ml, što je utvrđeno analizom nepoznato = neuspjeh u 48. tjednu.
Seventy-six percent were male, 82% were Black and 18% were White. 
Sedamdeset šest posto bili su muškarci, 82% bili su crnci, a 18% bijelci.
atorvastatin and pitavastatin 
atorvastatin i pitavastatin
Voxilaprevir: 
Voksilaprevir:
In phenotypic analyses of patients in the final resistance analysis population, 7 of 22 patients (32%) had HIV-1 isolates with reduced susceptibility to elvitegravir in the Genvoya group compared with HIV-1 isolates from 7 of 20 patients (35%) in the E/C/F/TDF group, HIV-1 isolates from 8 patients (36%) had reduced susceptibility to emtricitabine in the Genvoya group compared with HIV-1 isolates from 7 patients (35%) in the E/C/F/TDF group. 
U fenotipskim analizama bolesnika iz populacije za analizu konačne rezistencije, 7 od 22 bolesnika (32%) je imalo HIV-1 izolate sa smanjenom osjetljivošću na elvitegravir u skupini liječenoj lijekom Genvoya u usporedbi s HIV-1 izolatima 7 od 20 bolesnika (35%) u skupini koja je primala E/C/F/TDF, HIV-1 izolati 8 bolesnika (36%) imali su smanjenu osjetljivost na emtricitabin u skupini liječenoj lijekom Genvoya u usporedbi s HIV-1 izolatima od 47 bolesnika (35%) u skupini koja je primala E/C/F/TDF.
Changes in measures of bone mineral density 
Promjene u izmjerenoj mineralnoj gustoći kosti
There were no new safety issues identified in patients with end stage renal disease on chronic haemodialysis receiving Genvoya (see section 4.8). 
Nije bilo utvrđenih novih sigurnosnih pitanja u bolesnika sa završnim stadijem bolesti bubrega na kroničnoj hemodijalizi koji su primali lijek Genvoya (vidjeti dio 4.8).
Up to Week 144, the development of one or more primary elvitegravir, emtricitabine, or tenofovir alafenamide resistance-associated mutations was observed in HIV-1 isolates from 12 of 22 patients with evaluable genotypic data from paired baseline and Genvoya treatment-failure isolates (12 of 866 patients [1.4%]) compared with 12 of 20 treatment-failure isolates from patients with evaluable genotypic data in the E/C/F/TDF treatment group (12 of 867 patients [1.4%]). 
Do 144. tjedna uočena je jedna ili više primarnih mutacija povezanih s rezistencijom na elvitegravir, emtricitabin ili tenofoviralafenamid u HIV-1 izolatima 12 od 22 bolesnika s procjenjivim genotipskim podacima iz uparene početne vrijednosti i izolata iz neuspješnog liječenja lijekom Genvoya (12 od 866 bolesnika [1,4%]) u usporedbi s 12 od 20 izolata od bolesnika s procjenjivim genotipskim podacima iz skupine neuspješnog liječenja E/C/F/TDF (12 od 867 bolesnika [1,4%]).
Elvitegravir is 98-99% bound to human plasma proteins and binding is independent of drug concentration over the range of 1 ng/mL to 1.6 µg/mL. 
Elvitegravir je 98-99% vezan za proteine u plazmi ljudi i vezivanje je neovisno o koncentraciji lijeka u rasponu od 1 ng/ml do 1,6 µg/ml.
Co-administration of Genvoya and some medicinal products that are primarily metabolised by CYP3A may result in increased plasma concentrations of these products, which are associated with the potential for serious or life-threatening adverse reactions such as peripheral vasospasm or ischaemia (e.g., dihydroergotamine, ergotamine, ergometrine), or myopathy, including rhabdomyolysis (e.g., simvastatin, lovastatin), or prolonged or increased sedation or respiratory depression (e.g., orally administered midazolam or triazolam). 
Istodobna primjena lijeka Genvoya i nekih lijekova koje prvenstveno metabolizira CYP3A može rezultirati povećanim koncentracijama tih lijekova u plazmi, koje su povezane s potencijalno ozbiljnim ili životno opasnim nuspojavama, kao što su periferni vazospazam ili ishemija (npr. dihidroergotamin, ergotamin, ergometrin) ili miopatija, uključujući i rabdomiolizu (npr. simvastatin, lovastatin) ili dugotrajna ili povećana sedacija ili respiratorna depresija (npr. midazolam primijenjen peroralno,
In studies in treatment-naïve patients, Genvoya was associated with smaller reductions in bone mineral density (BMD) compared to E/C/F/TDF as measured by DXA analysis of hip (mean change: -0.8% versus -3.4%, p < 0.001) and lumbar spine (mean change: -0.9% versus -3.0%, p < 0.001) after 144 weeks of treatment. 
U ispitivanjima u bolesnika koji prethodno nisu bili liječeni, lijek Genvoya bio je povezan s manjim smanjenjima mineralne gustoće kosti (BMD) u usporedbi s E/C/F/TDF izmjereno DXA analizom kuka (srednja vrijednost promjene: -0,8% naspram -3,4%, p < 0,001) i lumbalne kralježnice (srednja vrijednost promjene: -0,9% naspram -3,0%, p < 0,001) nakon 144 tjedna liječenja.
Tenofovir diphosphate inhibits HIV replication through incorporation into viral DNA by the HIV RT, which results in DNA chain-termination. 
Tenofovirdifosfat inhibira replikaciju HIV-a ugradnjom u virusnu DNK pomoću HIV RT što dovodi do prekida lanca DNK.
Nineteen percent of patients were identified as Hispanic/Latino. 
Devetnaest posto bolesnika identificirano je kao Hispanoamerikanci/Latinoamerikanci.
All corticosteroids excluding cutaneous products Corticosteroids primarily metabolised by CYP3A (including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone). 
Kortikosteroidi koji se prvenstveno metaboliziraju putem CYP3A (uključujući betametazon, budezonid, flutikazon, mometazon, prednizon, triamcinolon).
Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue). 
Tenofoviralafenamid je nukleotidni inhibitor reverzne transkriptaze (NtRTI) i fosforoamidatni prolijek tenofovira (analog 2'-deoksiadenozin monofosfata).
Carbamazepine decreases plasma concentrations of elvitegravir and cobicistat, which may result in loss of therapeutic effect and development of resistance. 
Karbamazepin smanjuje koncentracije elvitegravira i kobicistata u plazmi, što može dovesti do gubitka terapijskog učinka i razvoja rezistencije.
Based on data from an in vitro study, co-administration of tenofovir alafenamide and xanthine oxidase inhibitors (e.g., febuxostat) is not expected to increase systemic exposure to tenofovir in vivo. 
Na temelju podataka in vitro ispitivanja ne očekuje se da će istodobna primjena tenofoviralafenamida i inhibitora ksantin oksidaze (npr. febuksostata) povećati sistemsku izloženost tenofoviru in vivo.
The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 144 was 0.2 (-0.3, 0.7) in the Genvoya group and 0.1 (-0.4, 0.6) in the E/C/F/TDF group (p = 0.006 for the difference between treatment groups). 
Medijan (Q1, Q3) promjene omjera ukupnog kolesterola i HDL kolesterola od početne vrijednosti u 144. tjednu bio je 0,2 (-0,3; 0,7) u skupini liječenoj lijekom Genvoya i 0,1 (-0,4; 0,6) u skupini liječenoj E/C/F/TDF (p = 0,006 za razliku između liječenih skupina).
Thirteen percent of patients were identified as Hispanic/Latino. 
Trinaest posto su identificirani kao Hispanoamerikanci/Latinoamerikanci.
Dose modifications are not necessary when administered in combination with Genvoya. 
Izmjene doze nisu potrebne kada se primjenjuje u kombinaciji s lijekom Genvoya.
In vitro and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP-mediated interactions involving emtricitabine with other medicinal products is low. 
In vitro i klinička farmakokinetička ispitivanja interakcija lijekova pokazala su da je mogućnost interakcija posredovanih CYP sustavom za emtricitabin s drugim lijekovima mala.
However, upon co-administration with cobicistat in Genvoya, near maximal inhibition of P-gp by cobicistat is achieved leading to increased availability of tenofovir alafenamide with resulting exposures comparable to tenofovir alafenamide 25 mg administered alone. 
Ipak, pri istodobnoj primjeni s kobicistatom u lijeku Genvoya, dostigne se gotovo maksimalna inhibicija P-gp-a kobicistatom te dolazi do porasta raspoloživosti tenofoviralafenamida, što dovodi do izloženosti koja je usporediva s izloženošću pri primjeni 25 mg tenofoviralafenamida u monoterapiji.
• anticoagulants, used to prevent and treat blood clots, such as: apixaban, edoxaban, rivaroxaban and warfarin 
• antikoagulanse, primjenjuju se za sprječavanje i liječenje krvnih ugrušaka, kao što su: apiksaban, edoksaban, rivaroksaban i varfarin